Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease (Q24200285)

Cochrane Database of Systematic Reviews

ChEBI release 2020-05-28

Reto Baldinger

1

0 references

Hans Dieter Katzberg

series ordinal

2

0 references

Markus Weber

series ordinal

3

0 references

publication date

18 April 2012

0 references

published in

0 references

cites work

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A pilot trial of dextromethorphan in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A randomized controlled trial of resistance exercise in individuals with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

No effect of creatine on respiratory distress in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Cerebrospinal fluid filtration in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Few adverse effects of long-term creatine supplementation in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Electrophysiological observations in patients with motor neuron disease receiving a thyrotropin releasing hormone analogue (RX77368)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Elevated plasma glucagon in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Long-term safety of riluzole in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Xaliproden in amyotrophic lateral sclerosis: early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Thalidomide causes sinus bradycardia in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A clinical trial of verapamil in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Transfer factor is ineffective in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Therapeutic trial of tilorone in ALS: Lack of benefit in a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Minocycline in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Reversible cognitive decline during high-dose alpha-interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

L-threonine as a symptomatic treatment for amyotrophic lateral sclerosis (ALS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Recombinant growth hormone treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Riluzole and D-amphetamine interactions in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Double-blind study of modified neurotoxin in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Quinine for muscle cramps

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A survey of clinicians' practice in the symptomatic treatment of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Amyotrophic lateral sclerosis. A study of its presentation and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Excitability properties of motor axons in patients with spontaneous motor unit activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

The origin of muscle fasciculations and cramps

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Quinine for nocturnal leg cramps: a meta-analysis including unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the Am

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Muscle cramp as the result of impaired GABA function--an electrophysiological and pharmacological observation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Possible mechanisms of muscle cramp from temporal and spatial surface EMG characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Gabapentin treatment for muscle cramps: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Interventions for leg cramps in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

RETRACTED: Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Trial of Baclofen in Amyotrophic Lateral Sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Trial of celecoxib in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

The influence of muscular lengthening on cramps

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A double-blind placebo-controlled trial ofl-threonine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Protirelin tartrate (TRH-T) in upper motoneuron syndrome: a controlled neurophysiological and clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Classification of amyotrophic lateral sclerosis cases at presentation in epidemiological studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Clinical problems in neuromuscular physiology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

An electromyographic study of induced and spontaneous muscle cramps

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Efficacy of hydroquinine in preventing frequent ordinary muscle cramp outlasts actual administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

The value of muscle exercise in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

The natural history and the effects of gabapentin in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Riluzole has no acute effect on motor unit parameters in ALS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Randomised controlled trial of hydroquinine in muscle cramps

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Glycocyamine and betaine in motor-neurone disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Randomised controlled trial of hydroquinine in muscle cramps

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Afterdischarge activity in neuropathic patients with frequent muscle cramps

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Trial of oral physostigmine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Low-dose prazosin in patients with muscle cramps during hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Disturbance of the water and electrolyte balance during high-dose interferon treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Motor neuron 'bistability'. A pathogenetic mechanism for cramps and myokymia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Human motor unit activity during induced muscle cramp

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Can nimodipine affect progression of motor neuron disease? A double-blind pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A clinical trial of dextromethorphan in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Acute action of aminophylline in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Randomized controlled phase II trial of glatiramer acetate in ALS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

The use of isoprinosine in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

The administration of guanidine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Amantadine and guanidine are ineffective in ALS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Trial of octacosanol in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A randomized trial of botulinum toxin A for treatment of drooling

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004157.PUB2

7 January 2021